Yellow Dye 5 vs Recombinant Bovine Growth Hormone: which is worse?

What is Yellow Dye 5?

Yellow Dye 5 (tartrazine) is a synthetic lemon-yellow azo dye derived from petroleum. It produces a bright, stable yellow color in acidic conditions and is one of the most widely used yellow dyes globally. Its chemical formula is C16H9N4Na3O9S2.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Yellow Dye 5: Yellow Dye 5 was one of six dyes studied in the landmark 2007 McCann et al. study in The Lancet. The study found statistically significant increases in hyperactivity in children ages 3 and 8–9 given a mixture containing tartrazine and sodium benzoate. EFSA reviewed the evidence and confirmed the effect was real, mandating the EU warning label from 2010. A 2012 review in Neurotherapeutics (Arnold et al.) confirmed that artificial food colors including tartrazine have a small but statistically significant adverse effect on children's behavior that is not confined to those with diagnosed ADHD. Tartrazine is one of the most documented causes of food dye hypersensitivity. Cross-reactivity with aspirin (acetylsalicylic acid, ASA) is well established in allergy literature: individuals with aspirin hypersensitivity have elevated risk of reacting to tartrazine. Symptoms include urticaria, angioedema, rhinitis, and in rare cases anaphylaxis. Prevalence of tartrazine sensitivity is estimated at 0.1% of the population but higher in aspirin-sensitive individuals. Because of this known hypersensitivity risk, the FDA specifically requires Yellow No. 5 to be declared by name on US food labels — an exceptional requirement not applied to most other additives, reflecting the FDA's acknowledgment of this real clinical concern. EFSA's 2009 re-evaluation found no evidence of genotoxicity in standard test systems at food use levels, setting an ADI of 7.5 mg/kg body weight, but noted in vitro evidence at higher doses. In April 2025, the FDA announced plans to phase out Yellow 5 along with other petroleum-based dyes.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.